< Back

Mounjaro

MED-000003

Mounjaro® (tirzepatide) is a once-weekly dual GLP-1/GIP receptor agonist approved to improve blood sugar control in adults with type 2 diabetes, alongside diet and exercise. It also carries a cardiovascular indication, with 2025 label updates showing reduced risk of cardiovascular death or worsening heart failure in adults with heart failure with preserved ejection fraction (HFpEF).

Medication Overview

Generic Name:

Medication Class:

Manufacturer:

Route:

Dosing Frequency:

Tirzepatide

GLP-1/GIP

Eli Lilly

Injection

Weekly

Status:

Draft

Medication Summary

Aliases

Tirzepatide

Search Keywords

mounjaro, tirzepatide, GLP-1, GIP, type 2 diabetes

Medication Uses

Part of the DietApp.com GLP-1 Medication Database, a comprehensive, regularly reviewed reference covering every GLP-1-class medication.

Mounjaro® (tirzepatide) is an FDA-approved dual GIP/GLP-1 receptor agonist indicated as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes. Mounjaro also carries a cardiovascular indication: reducing the risk of cardiovascular death or worsening heart failure in adults with heart failure with preserved ejection fraction (HFpEF), added to the label in 2025 based on results from the SUMMIT trial, which showed a 38% reduction in this combined outcome. Mounjaro is not approved for type 1 diabetes, diabetic ketoacidosis, or chronic weight management specifically — that indication belongs to Zepbound.

Dosage

Mounjaro is injected once weekly, subcutaneously: - Weeks 1–4: 2.5 mg (starting dose, not intended for blood sugar control on its own) - Weeks 5–8: 5 mg - Weeks 9–12: 7.5 mg - Weeks 13–16: 10 mg - Weeks 17–20: 12.5 mg - Week 21 onward: 15 mg (maximum dose) Approved maintenance doses are 5 mg, 10 mg, or 15 mg once weekly, based on individual response and tolerability. If a dose is missed, it can be administered within 4 days; beyond that, skip and resume your regular schedule.

Administration

Subcutaneous injection, once weekly, any time of day, with or without food. Inject into the abdomen, thigh, or upper arm, rotating sites to reduce irritation. If also using insulin, administer as a separate injection — never mix the two products.

Benefits

When used as prescribed, Mounjaro may help: - Lower blood sugar (A1C) levels in adults with type 2 diabetes - Reduce the risk of cardiovascular death or worsening heart failure in adults with HFpEF - Support meaningful weight loss as a secondary effect, though Mounjaro is not FDA-approved specifically for weight management (that indication belongs to Zepbound)

Side Effects

The most frequently reported side effects include: - Nausea - Diarrhea - Vomiting - Constipation - Decreased appetite - Injection-site reactions Most noticeable during dose escalation, often improving with continued use.

Warnings

Mounjaro carries an FDA boxed warning regarding thyroid C-cell tumor risk observed in rodent studies. Contraindicated in patients with: - A personal or family history of medullary thyroid carcinoma (MTC) - Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) Other important warnings include: - Pancreatitis - Acute kidney injury, typically linked to dehydration from GI side effects - Gallbladder disease - Diabetic retinopathy complications - Serious hypersensitivity reactions Seek immediate medical attention for severe abdominal pain, difficulty breathing, or facial/throat swelling.

Drug Interactions

Particular caution is needed with: - Insulin and sulfonylureas — increased hypoglycemia risk; a dose reduction may be needed - Oral medications generally — Mounjaro delays gastric emptying, which can affect absorption - Oral hormonal contraceptives — Mounjaro has been shown to meaningfully reduce peak drug concentrations; discuss alternative contraception with your provider Never share a Mounjaro pen between patients, even with a new needle.

Storage

Before first use: refrigerate at 36°F–46°F (2°C–8°C). Do not freeze. After first use: refrigerate, or store at room temperature (up to 86°F/30°C) for up to 21 days. Protect from light and heat. Keep out of reach of children.

References

- U.S. FDA prescribing information for Mounjaro® - DailyMed prescribing information - American Diabetes Association Standards of Care - Eli Lilly Healthcare Professional prescribing information

Last medically reviewed and updated: July 11, 2026.

Track Your Progress

Managing type 2 diabetes with Mounjaro is a long-term process. With DietApp.com, you can: - Record weekly injections and titration progress - Track blood sugar patterns alongside meals - Monitor weight trends over time - Log meals, hydration, and physical activity - Record side effects and symptoms - Prepare an organized treatment history for healthcare appointments

Download DietApp.com

Related Resources

- Tirzepatide Medication Guide - Zepbound Medication Guide - GLP-1 Medication Library - Type 2 Diabetes Management Resources - GLP-1 Injection Guide - Medication Safety Information

- What Is Tirzepatide? - Mounjaro vs. Zepbound: What's the Difference? - Tirzepatide Side Effects: What Patients Need to Know - How GLP-1 Medications Support Blood Sugar Control - Frequently Asked Questions About GLP-1 Therapy

More From DietApp.com

Explore the full GLP-1 Tracker knowledge base on DietApp.com

Explore DietApp.com Tools

- BMI Calculator — Get an instant estimate and see what it does (and doesn't) tell you about your health - GLP-1 Dose & Injection Tracker — Log your weekly dose and rotate injection sites automatically - AI Food Recognition — Snap a photo of your meal for instant protein, fiber, and calorie tracking - Protein & Hydration Dashboard — See your daily totals at a glance - Symptom & Side Effect Log — Track patterns over time to bring to your next appointment - Download DietApp — Start tracking your GLP-1 journey today

About DietApp.com

DietApp.com combines evidence-based GLP-1 medication education with practical treatment tracking tools. The information on DietApp.com is intended for educational purposes only and should not replace professional medical advice, diagnosis, or treatment.